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Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) are highly prevalent,
chronic conditions with intriguing, yet poorly understood epidemiological overlap. To
date, the amount of OSA syndrome present in patients with AD across literature
remains unknown. To address this question, we collected all available published clinical
data and analyzed them through a quantitative meta-analytical approach. The results
of our quantitative meta-analysis suggest that the aggregate odds ratio for OSA
in AD vs. healthy control was 5.05 and homogeneous. This reflects that patients
with AD have a five times higher chance of presenting with OSA than cognitively
non-impaired individuals of similar age. Moreover, these data suggest that around half
of patients with AD have experienced OSA at some point after their initial diagnosis.
The additive impact of progressive changes in sleep quality and structure, changes
in cerebral blood flow and the cellular redox status in OSA patients may all be
contributing factors to cognitive decline and may further aggravate AD progression.
It is hoped that the high OSA rate in AD patients, as suggested by the findings of
our meta-analysis, might provide a sufficient clinical incentive to alert clinicians the
importance of screening patients for OSA in AD, and stimulate further research in
this area.
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INTRODUCTION
Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) are highly prevalent, chronic
conditions with intriguing, yet poorly understood epidemiological overlaps (Ancoli-Israel
et al., 1991; Khazaie et al., 2011, 2013; Chan et al., 2013; Khazaie and Maroufi, 2014; Pan and
Kastin, 2014; Reitz and Mayeux, 2014; Heinzer et al., 2015; Peter-Derex et al., 2015; Rosenzweig
et al., 2015; Khaledi-Paveh et al., 2016). From a clinical perspective, it is important to know
the prevalence of OSA in patients with AD, as well as the incidence of AD in patients with OSA,
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in order to plan resources and modify treatment for
co-morbidities (Pan and Kastin, 2014; Osorio et al., 2015).
Preclinical studies, suggest a causal relationship between
untreated OSA and instigation of neurodegenerative processes
underlying AD, although the process is far from clear (Pan and
Kastin, 2014; Rosenzweig et al., 2015). Nonetheless, the results
of several studies suggest that OSA might be a reversible cause
of cognitive impairment and dementia, and that treatment of
OSA, particularly in the early stages of AD, when patients are
still largely independent, may decelerate dementia progression
(Ancoli-Israel et al., 2008; Cooke et al., 2009b; Troussière et al.,
2014). Correlation between symptoms of OSA and cognitive
impairment has been shown in patients with dementia (Ancoli-
Israel and Coy, 1994). For example, a study that investigated
AD patients in a nursing home setting has found that those
with severe dementia had significantly more severe OSA
compared to those with mild to moderate or no dementia,
and that those with more severe OSA had significantly more
severe dementia (Ancoli-Israel et al., 1991). Similarly, the
gold standard treatment for OSA, continuous positive airway
pressure (CPAP), has been shown to be partially effective in
improving episodic verbal learning, memory, cognitive flexibility
and mental processing speed in patients with co-morbid AD
and OSA (Ancoli-Israel et al., 2008). In another preliminary
study, long-term CPAP treatment was associated with a lasting
improvement in sleep and mood, as well as a slowing of
cognitive deterioration in AD (Cooke et al., 2009b). In a
further study of patients with mild to moderate AD, CPAP was
shown to result in deeper sleep after just one night, and these
improvements were maintained for several weeks (Cooke et al.,
2009a).
It has been reported that OSAmay induce neuroinflammatory
and neurotrophic changes in affected and susceptible patients,
and OSA-induced brain injury has been demonstrated in animal
experimental models (Xu et al., 2004; Lavie, 2015; Rosenzweig
et al., 2015). In OSA, nocturnal episodes of complete or
partial pharyngeal obstruction result in intermittent hypoxia,
reoxygenation, and sleep fragmentation (Malhotra et al., 2015).
Serious cardiovascular and metabolic co-morbidities can be
associated with OSA (Malhotra et al., 2015), and they may
independently contribute to, and further aggravate, progression
and severity of AD (Bliwise, 2013). The additive impact of
progressive changes in sleep quality and structure, changes
in cerebral blood flow, neurovascular and neurotransmitter
changes, and the cellular redox status and neural regulation
in OSA patients may all constitute contributing factors to
further cognitive decline, as well as to aggravate progression
of AD (Rosenzweig et al., 2014, 2015; Veasey, 2014; Lavie,
2015).
To date, the magnitude of the OSA observed in patients with
AD remains unknown, with only a few (likely underpowered
studies) available in the literature (Bliwise, 2013). The aim
of this study was to provide a more convergent answer
regarding the presence of OSA in patients with AD. To
achieve this aim, whilst recognizing the constraints of smaller
single studies, we undertook to find and collect all available
published clinical data across applicable studies, and to analyze
it through a more powerful, quantitative meta-analytical
approach.
MATERIALS AND METHODS
Following the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement (Moher et al., 2009),
search of medical literature via PubMed was carried out in
July 2015 We used the following key terms: (‘‘Sleep Apnea
Syndromes’’ [Mesh] OR ‘‘Sleep Apnea, Obstructive’’ [Mesh] OR
‘‘Sleep Apnea’’) AND (‘‘AD’’ OR Alzheimer’s disease [Mesh]).
Further studies were identified through reviewing studies and
reference tracing of retrieved articles. We included any study
reporting prevalence of OSA in AD. Exclusion criteria were
as follows: (1) case reports, reviews, meta-analysis, or animal
studies; (2) non-AD studies (e.g., studies on other dementia
or mild cognitive impairment (MCI) patients); (3) non-OSA
studies (e.g., studies on sleep fragmentation or central sleep
apnea); (4) interventional studies (e.g., CPAP or treatment
effects); and (5) duplicate material. The search of the literature
was subsequently updated on December 2015 and Alzheimer’s
Dementia was included in the list of key terms. No new study
met our criteria to be included.
For each study, the total number of AD patients and number
of AD patients with OSA was extracted. When possible, similarly
this approach was implemented for healthy control subjects’ data.
These data allowed us to calculate an odd ratio (OR) for each
study and subsequently an aggregate measure using the Biostat’s
statistical package (Borenstein et al., 2005). For the analysis,
random effect model was selected a priori. The OR measurement
allowed us to estimate the difference in occurrence of OSA
in AD compared to healthy control. In the event of limited
dataset, we have run sensitivity analysis with select moderating
variables. By the same token, investigation of heterogeneity
and publication bias was carried out when applicable. Each
study provided sufficient data for sensitivity analysis on the
AD patients including, gender, average age, MMSE score, and
dementia rating. For all other selected variables, if less than three
studies reported data, no analyses were undertaken.
RESULTS
Description of the Study Selection
The initial electronic search from PubMed yielded 102 articles.
In addition, four further manuscripts were found from other
sources (see below). Of these 102 articles, 61 studies were reviews
and were therefore excluded, a further five were excluded because
they studied animal models, three studies were case reports, eight
studies did not include any patients with Alzheimer’s Dementia,
six studies did not consider any OSA patients, seven were about
CPAP effects and a further seven were not deemed relevant
(for example: two studies were on medication effects, one was
about the relationship between OSA and cerebrovascular disease
markers, two studies were not case-controls, one was a molecular
study and the final excluded study was about autopsy data).
Based on our predetermined exclusion criteria, the following four
studies from the additional reference tracking were excluded: two
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FIGURE 1 | Flow chart depicting article selection strategy.
were a duplication from our PubMed search (Reynolds et al.,
1985; Hoch et al., 1986), one study was about episodic memory
and not directly AD (Daurat et al., 2008) and the final study was
not a case control study (Yaffe et al., 2011; Figure 1). The final
summary of the five included cross-sectional studies (Smallwood
et al., 1983; Reynolds et al., 1985, 1987; Hoch et al., 1986, 1989) is
presented in Table 1.
Description of the Five Cross-Sectional
Included Studies
In the included studies, numbers of patients ranged from 15
and 24, and healthy controls from 12 to 56. The majority
of studies investigated female patients, with the exception of
one study that reported on 73.3% male patients. The age of
the patients ranged from 65.5 to 74.5 years across studies.
AD was diagnosed predominantly according to Diagnostic
and Statistical Manual of Mental Disorders (DSM-III) criteria
(Kendell, 1980) for AD (4/5 studies) and only one study
(Hoch et al., 1989) used both the DSM-III and the NINCDS-
ADRDA Alzheimer’s Criteria, which were proposed in 1984
by the National Institute of Neurological and Communicative
Disorders and Stroke and the AD and Related Disorders
Association (McKhann et al., 1984) and; and four study explicitly
specified probable AD. In terms of education, the groups were
uneven in that controls on average were more educated than
the patients; controls number of years of education ranged from
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TABLE 1 | Demographic representation of the included cross-sectional studies.
Variables Groups Hoch et al. (1989) Reynolds et al. (1987) Hoch et al. (1986) Reynolds et al. (1985) Smallwood et al. (1983)
Number of subjects Patients 15 15 24 21 15
Controls 12 15 56 23 40
Number of males (%) Patients 2 (13.33%) 0 (0%) 6 (25%) 6 (28.5%) 11 (73.3%)
Controls 5 (41.6%) 3 (20%) 27 (48.21%) 9 (39.1%) 34 (85%)
Age (years) Patients 74.5 ± 5.1 73.3 ± 9.1 71.5 ± 8.1 70.3 ± 7.9 65.5 ± 2.3 (male)
69.5 ± 4.4 (female)
Controls 70.2 ± 5.6 72.6 ± 7.8 69.3 ± 5.4 69.3 ± 5.6 Male (60 ± 1.31)
Female (65.5 ± 2.2)
Young male (25.2 ± 0.59)
BMI Patients 22.8 ± 4.2 21.9 ± 4.7 20% of ideal 20% ideal ±15% of ideal
(n = 12) bodyweight body weight body weight
Controls 27.2 ± 5.3 27.1 ± 5.0 20% of ideal 20% ideal ±15% of ideal
(n = 13) body weight body weight body weight
Education (years) Patients 11.1 ± 4.3 – 11.3 ± 4.1 11.3 ± 4.1 –
Controls 12.9 ± 3.7 – 14.8 ± 3.8 15.4 ± 4.1 –
Dementia diagnosis Patients NICNDS-ADRDA, DSMIII DSMIII DSMIII DSM III
criteria DSMIII
Folstein mini-mental Patients 17.2 ± 7.2 15.7 ± 8.7 18 ± 4.6 18.2 ± 4.9 –
state score (MMSE)
Controls 29.3 ± 0.6 29.2 ± 0.7 29.3 ± 0.8 29.3 ± 0.9 –
Hachinski ischemia score Patients 1.0 ± 0.8 1.2 ± 1.3 1.1 ± 1.1 1.9 ± 1.3 –
Controls 1.1 ± 0.8 1.2 ± 0.9 0.8 ± 0.7 1.1 ± 0.9 –
Dementia rating scale Patients 10.7 ± 4.0 10.1 ± 5.8 8.6 ± 5.5 8.5 ± 4.8 –
OSA diagnosis method Patients PSG 24-chanel polygraphs PSG PSG Respiratory inductive
(Grass 78B) plethysmography
Controls PSG 24-chanel polygraphs PSG PSG Respiratory inductive
(Grass 78B) plethysmography
OSA % Patients 53.33% 38% 41.66 42.85% 53.33%
Controls 33.33% 13% 5.35% 4.34% 27.5%
Note: OSA: obstructive sleep apnea; DSM: the Diagnostic and Statistical Manual of Mental Disorders; NICNDS-ADRDA: National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; PSG: polysomnography.
12.9 to 15.4 years vs. patients number of years of education
ranged from 11.1 to 11.3. Folstein mini-mental state score
was utilized in four out of five studies and it ranged from
15.7 to 18.2. Dementia Rating Scale was reported in three of
four studies and ranged from 8.5 to 10.7. All data emerged
from published studies with samples from the USA (Table 1).
There was heterogeneity across studies in terms of how OSA
was assessed; 3 of 5 studies used polysomnography, while
others used either 24-chanel polygraph or respiratory inductive
plethysmography.
Effect Size, Heterogeneity, and
Measurement of Bias
The aggregate odds ratio for the occurrence of OSA in AD vs.
healthy control was 5.05 [N = 5; 95% confidence interval (CI):
2.41–10.56, P-value< 0.001;Q-value: 4.44; P-value: 0.35; I2: 9.85]
and homogeneous. It is of note that only two of the five studies
(Reynolds et al., 1985; Hoch et al., 1986) showed significant 95%
CI, which may suggest that each study weights differently in the
analysis. In fact, these two studies, have the largest sample in the
AD study arm. With the broad 95% CI in mind and the level of
significance (alpha 0.05), this effect size, odds ratio, suggests that
OSA occurs 5.05 times more in AD than in healthy controls. For
odds ratio analysis, of the 90 AD enrolled patients, 41 had OSA
(∼45%), and of the 146 healthy controls, 21 had OSA (∼14%;
Figure 2). This suggests that nearly 50% of the investigated
AD patients experienced OSA at some time after diagnosis. For
publication bias analysis, two quantitative statistics, the Begg and
Mazumdar rank correlation for Kendall’s tau with and without
continuity correction and Egger’s regression intercept were non-
significant at alpha 0.05. The non-significant results for the
Begg and Mazumdar, and Egger’s regression provide evidence
to suggest the lack of publication bias with the current set of
studies.
Sensitivity Analysis
Single variable meta-regression using mixed effect (method
of moments) with AD parameters, showed no significant
effect of percent male [Point estimate: 0.006; P-value:
0.517;N = 5], average age [Point estimate:−0.056; P-value: 0.304;
N = 5], MMSE score [Point estimate: 0.566; P-value: 0.230;
N = 4], dementia rating scale score [Point estimate: −0.831;
P-value: 0.063; N = 4], and Hachinski ischemia score [Point
estimate: 1.521; P-value: 0.318;N = 4] onOSA odds of occurrence
in AD patients vs. healthy control.
The OSA assessment approach affected the OR’s magnitude.
For 3 out of 5 studies that used the PSG approach, the OR
was 7.248, 95%CI ranged between 2.121 and 24.771, it was
significant (P-value: 0.002), and homogeneous [Q-value: 3.201;
P-value: 0.202; I2: 37.567]. For the other two studies, given
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FIGURE 2 | Forest plot shows the aggregate comparison between patients with Alzheimer’s disease (AD) and healthy controls in terms of obstructive
sleep apnea (OSA). CI, confidence interval.
the heterogeneity in the approach and number of studies
for analysis, no further analysis was conducted. Similarly, the
aggregate OR was larger for the studies explicitly reporting on
probable AD [OR: 6.335; 95%CI: 2.540–15.803; P-value: 0.001,
N = 4].
No further analysis could be done on the effect of BMI given
the heterogeneity in the methods on reporting data and low
number of studies. Given the ratio of the overall number of
studies to number of variables examined, the sensitivity analyses
data should be interpreted with caution.
DISCUSSION
The results of our meta-analysis suggest that patients with AD
have five times higher chance of presenting with OSA compared
to cognitively non-impaired individuals of similar age. Our data
further suggest that in these studies, around 50% of patients
with AD have experienced OSA at some time after their initial
diagnosis.
Whilst our data cannot be taken to suggest causality or
direction of the temporal relationship between two debilitating
disorders, it certainly raises questions about the possible clinical
risk of their additive impact. OSA has been shown to cause
progressive central nervous changes and excessive daytime
somnolence in susceptible patients, and this can contribute to
further cognitive decline or AD progression (Rosenzweig et al.,
2013, 2015). Any intervention that improves cognition in
patients with dementia is likely to have broad impact, since
improved daily function implies greater independence for the
patient, less caregiver burden, fewer nursing service and social
support needs, and generally reduced disease-associated costs
(Cooke et al., 2009b; Bliwise, 2013). Currently there are only a
few studies that explored the impact of treatment with CPAP of
OSA on AD course, and some clinicians argue that the current
evidence for cognitive benefits is not sufficient to dictate that
treatment as imperative for all patients (Ancoli-Israel et al., 2008;
Cooke et al., 2009a; Bliwise, 2013; Troussière et al., 2014; Osorio
et al., 2015). Nonetheless, there appears to be evidence to suggest
that CPAP is beneficial in treating hypersomnolence and sleep
integrity in some patients with AD (Bliwise, 2013). Also, several
studies over years have shown an indirect association between
excessive daytime sleepiness and the development of cognitive
decline (Jaussent et al., 2012; Keage et al., 2012). Additionally,
beneficial effects of treatment of OSA, on cognitive performance,
vigilance and excessive daytime sleepiness have been shown in
recent meta-analyses (Marshall et al., 2006; Olaithe et al., 2014)
and a meta review (Bucks et al., 2013). These data have recently
been extended to show the beneficial effects of the CPAP therapy
on excessive daytime sleepiness in older OSA patients (McMillan
et al., 2014).
Fewer studies, have investigated the link between OSA and
the onset of MCI and AD. A recent study of a well-characterized
longitudinal cohort (the AD Neuroimaging Initiative (ADNI)
cohort), has reported a significant association of sleep-disordered
breathing with an earlier age at MCI and AD onset (Osorio
et al., 2015). In this study, OSA appeared to confer risk of
onset of AD, starting one decade earlier even when accounting
for possible confounding factors such as sex, APOε4 status,
diabetes, depression, BMI, cardiovascular disease, hypertension,
age at baseline, and education of participants. Moreover, this
link appeared significantly attenuated in those patients who used
CPAP, suggesting that use of CPAP may delay progression,
or onset, of MCI. The similar effect of CPAP on delay in
age at AD onset was not demonstrated in this study (Osorio
et al., 2015). Correspondingly, in an earlier study of 298
community-dwelling women, those with co-morbid OSA were
shown as more likely to develop MCI or dementia at the
5-year follow-up (Yaffe et al., 2011). In the same way, another
recent pilot study has demonstrated that CPAP treatment of
severe OSA, in mild-to-moderate AD patients was associated
with significantly slower cognitive decline over a 3-year follow-
up period (Troussière et al., 2014). Taken together, these data
emphasize the importance of detecting and treating OSA in this
population.
Analogously, an accumulating body of clinical and
pre-clinical research suggests that OSA might be one of
rare modifiable factors in the pathomechanisms of AD (Bliwise,
2013; Pan and Kastin, 2014; Osorio et al., 2015; Rosenzweig
et al., 2015). The association between OSA and cerebral
spinal fluid (CSF) AD-biomarker changes including elevated
CSF phosphorylated tau and β-amyloid 42 in elderly with
the APOε3/3 alleles has been demonstrated (Osorio et al.,
2014). By the same token, recent neuroimaging studies have
suggested that sleep disruption, such as those occurring
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during OSA, can presents a mechanistic pathway through
which β-amyloid pathology may contribute to hippocampus-
dependent cognitive decline in the elderly (Mander et al.,
2013, 2015). In addition, increasing evidence suggests that
AD and OSA pathogenesis includes strong interactions with
immunological mechanisms in the brain (Heneka et al., 2015a,b;
Rosenzweig et al., 2015). Genome-wide analysis further suggest
that several genes that increase the risk for sporadic AD
also encode factors that regulate glial clearance of misfolded
proteins and the inflammatory reaction (Heneka et al., 2015a)
Comparably, abnormal protein folding and neuroinflammation
have been also demonstrated or suggested by preclinical and
clinical OSA studies (Roussel et al., 2013; Rosenzweig et al.,
2015).
LIMITATIONS
Given the strong association between the two disorders, the
lack of epidemiological studies of co-morbid AD and OSA
undertaken to date is notable; our literature search yielded
only a few applicable studies, all conducted in the late
1980’s. Moreover, it is noteworthy that due to the clinical
and cognitive presentations of the enrolled patients and the
lack of reported neuroimaging or biomarkers data, we could
potentially acknowledge that most of these patients were of
probable AD. The small amount of available epidemiological
data reflects the difficulties in conducting overnight studies in
such a vulnerable patient population. Over the last two decades,
however, there has been significant progress in the diagnosis
of AD (Rhodius-Meester et al., 2015; Carmona et al., 2016;
Salvatore et al., 2016), and it is possible that our results are
not representative of the current socio-demographics, or indeed
of the current AD cohort. It is arguable that prevalence could
be even higher given that risks shared by both disorders (e.g.,
ageing and obesity) are on increase (Yaffe et al., 2014; Peter-
Derex et al., 2015; Rosenzweig et al., 2015; Willette et al.,
2015).
With this view, and keeping in mind the limitations
of our study, several other findings from our data merit
a further mention. In our study, healthy and otherwise
well-matched controls were found to be significantly more
educated than the patients. Previous studies have suggested
that individuals with higher education and higher occupational
attainment have a reduced risk of developing AD (Harris
et al., 2015). Indeed, it has been suggested that higher
cognitive reserve might protect against neurocognitive deficits
induced by OSA (Rosenzweig et al., 2015) Also of note,
in all but one study (Smallwood et al., 1983) women were
in the majority, suggesting either higher prevalence, or as
of yet unexplained recruitment bias on part of researchers
conducting those studies. It is known that OSA is more
prevalent in men than in women and that it increases
with age and obesity (Franklin and Lindberg, 2015). The
prevalence of OSA in women, however, is known to increase
significantly after menopause (Koo et al., 2016). Similarly, the
onset of menopause in women increases their risk of AD,
possibly due to depletion of estrogens (Christensen and Pike,
2015). This may be of particular clinical importance, as the
limited data available suggest that women with OSA may
have greater risk of hypertension and endothelial dysfunction,
and that they could be more likely to develop comorbid
conditions and have increased mortality (Christensen and
Pike, 2015). In addition, several authors have argued that
both aging and menopause contribute to increasing levels
of neuroinflammation, which, as mentioned, is increasingly
recognized as one of themajor pathomechanisms of AD andOSA
(Christensen and Pike, 2015; Heneka et al., 2015a; Rosenzweig
et al., 2015).
Due to the small number of original studies and their
relatively small patient cohorts, our study was not sufficiently
powered to investigate the effect of several important
confounding factors such as APOε4 status, diabetes, depression,
BMI, cardiovascular disease, hypertension. It is important
to acknowledge that, although the type of OSA assessment
affected the results, we did not examine the sensitivity of
each approach. However, none of these factors have been
shown to influence the efficacy of the CPAP treatment in
AD. Nevertheless, it could be argued that they could, present
a putative causal pathway for OSA and AD (Bliwise, 2013).
Given all the limitations, caution should be used when
interpreting our findings. To determine the interactions
between OSA and its treatment on AD progression or severity,
longitudinal epidemiological studies are needed that address
these limitations.
CONCLUSION
The accumulated impact of even small improvements in the
quality of life, health and associated lower therapy costs
for AD is likely to have enormous consequences when one
considers that it is a chronic disorder refractory to treatment
and that it carries a huge morbidity and mortality burden
to patient and their carers, local communities, and overall
society. Although currently there is no conclusive evidence that
treating OSA in AD will have a major impact on AD course
(Bliwise, 2013), several authors have argued that there is enough
clinical evidence to suggest CPAP treatment may be at least
beneficial in terms of alleviating daytime hypersomnolence,
excessive napping and lethargy, all of which are recognized,
and incapacitating problems in many AD patients (Bliwise,
2013). It has been further argued that, as long as there is
a realistic appraisal of what goals of intervention should be
expected, the treatment should be encouraged (Bliwise, 2013).
Moreover, clinicians have proposed that in selected cases,
treatment of OSA in AD patients may have dramatic effect;
the data reviewed in our study appears to further support
this empirical knowledge (Yaffe et al., 2011; Bliwise, 2013;
Troussière et al., 2014; Osorio et al., 2015). It is hoped that
the high occurrence of OSA in AD patients suggested by our
meta-analyses might alert clinicians to importance of screening
patients with AD for co-morbidities such as OSA. Future
prospective studies are required to confirm this association in
neuropathologically verified cases of AD, as well as to delineate
distinct interplay of co-morbid OSA with different types of
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neurodegenerative processes (e.g., in vascular vs. mixed dementia
vs. AD).
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